These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32922743)

  • 1. Gut microbiota modification suppresses the development of pulmonary arterial hypertension in an SU5416/hypoxia rat model.
    Sanada TJ; Hosomi K; Shoji H; Park J; Naito A; Ikubo Y; Yanagisawa A; Kobayashi T; Miwa H; Suda R; Sakao S; Mizuguchi K; Kunisawa J; Tanabe N; Tatsumi K
    Pulm Circ; 2020; 10(3):2045894020929147. PubMed ID: 32922743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of reactive oxygen species to the pathogenesis of pulmonary arterial hypertension.
    Jernigan NL; Naik JS; Weise-Cross L; Detweiler ND; Herbert LM; Yellowhair TR; Resta TC
    PLoS One; 2017; 12(6):e0180455. PubMed ID: 28666030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partially hydrolyzed guar gum suppresses the progression of pulmonary arterial hypertension in a SU5416/hypoxia rat model.
    Sanada TJ; Hosomi K; Park J; Naito A; Sakao S; Tanabe N; Kunisawa J; Tatsumi K; Suzuki T
    Pulm Circ; 2023 Jul; 13(3):e12266. PubMed ID: 37448440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SU5416 plus hypoxia but not selective VEGFR2 inhibition with cabozantinib plus hypoxia induces pulmonary hypertension in rats: potential role of BMPR2 signaling.
    Sitapara R; Sugarragchaa C; Zisman LS
    Pulm Circ; 2021; 11(3):20458940211021528. PubMed ID: 34178306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary Arterial Hypertension Affects the Rat Gut Microbiome.
    Callejo M; Mondejar-Parreño G; Barreira B; Izquierdo-Garcia JL; Morales-Cano D; Esquivel-Ruiz S; Moreno L; Cogolludo Á; Duarte J; Perez-Vizcaino F
    Sci Rep; 2018 Jun; 8(1):9681. PubMed ID: 29946072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MSCs Therapy Reverse the Gut Microbiota in Hypoxia-Induced Pulmonary Hypertension Mice.
    Luo L; Chen Q; Yang L; Zhang Z; Xu J; Gou D
    Front Physiol; 2021; 12():712139. PubMed ID: 34531759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with anti-gremlin 1 antibody ameliorates chronic hypoxia/SU5416-induced pulmonary arterial hypertension in mice.
    Ciuclan L; Sheppard K; Dong L; Sutton D; Duggan N; Hussey M; Simmons J; Morrell NW; Jarai G; Edwards M; Dubois G; Thomas M; Van Heeke G; England K
    Am J Pathol; 2013 Nov; 183(5):1461-73. PubMed ID: 24160323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perinatal hypoxia aggravates occlusive pulmonary vasculopathy in SU5416/hypoxia-treated rats later in life.
    Oshita H; Sawada H; Mitani Y; Tsuboya N; Kabwe JC; Maruyama J; Yusuf A; Ito H; Okamoto R; Otsuki S; Yodoya N; Ohashi H; Oya K; Kobayashi Y; Kobayashi I; Dohi K; Nishimura Y; Saitoh S; Maruyama K; Hirayama M
    Am J Physiol Lung Cell Mol Physiol; 2022 Aug; 323(2):L178-L192. PubMed ID: 35762603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paeoniflorin Ameliorates Chronic Hypoxia/SU5416-Induced Pulmonary Arterial Hypertension by Inhibiting Endothelial-to-Mesenchymal Transition.
    Yu M; Peng L; Liu P; Yang M; Zhou H; Ding Y; Wang J; Huang W; Tan Q; Wang Y; Xie W; Kong H; Wang H
    Drug Des Devel Ther; 2020; 14():1191-1202. PubMed ID: 32256050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel rat model of pulmonary hypertension induced by mono treatment with SU5416.
    Chen Y; Kuang M; Liu S; Hou C; Duan X; Yang K; He W; Liao J; Zheng Q; Zou G; Chen H; Yan H; Chen J; Li Y; Zhou Y; Luo X; Jiang Q; Tang H; Lu W; Wang J
    Hypertens Res; 2020 Aug; 43(8):754-764. PubMed ID: 32472112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fasudil Dichloroacetate Alleviates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension by Ameliorating Dysfunction of Pulmonary Arterial Smooth Muscle Cells.
    Liu P; Huang W; Ding Y; Wu J; Liang Z; Huang Z; Xie W; Kong H
    Drug Des Devel Ther; 2021; 15():1653-1666. PubMed ID: 33935492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Isoquinoline-Sulfonamide Compound H-1337 Attenuates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension in Rats.
    Shoji H; Yoshida Y; Sanada TJ; Naito A; Maruyama J; Zhang E; Sumi K; Sakao S; Maruyama K; Hidaka H; Tatsumi K
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Airway delivery of Streptococcus salivarius is sufficient to induce experimental pulmonary hypertension in rats.
    Zhang C; Zhang T; Xing Y; Lu W; Chen J; Luo X; Wu X; Liu S; Chen L; Zhang Z; Zhou D; Lin Z; Chen Y; Xiong M; Yuan JX; Yang K; Wang J
    Br J Pharmacol; 2023 Aug; 180(16):2102-2119. PubMed ID: 36869838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural reversal of pulmonary vascular remodeling and right ventricular remodeling in SU5416/hypoxia-treated Sprague-Dawley rats.
    Zungu-Edmondson M; Shults NV; Melnyk O; Suzuki YJ
    PLoS One; 2017; 12(8):e0182551. PubMed ID: 28809956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detrimental Impact of Vasopressin V2 Receptor Antagonism in a SU5416/Hypoxia/Normoxia-Exposed Rat Model of Pulmonary Arterial Hypertension.
    Goto I; Dohi K; Ogihara Y; Okamoto R; Yamada N; Mitani Y; Ito M
    Circ J; 2016; 80(4):989-97. PubMed ID: 26924211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-type natriuretic peptide does not attenuate the development of pulmonary hypertension caused by hypoxia and VEGF receptor blockade.
    Casserly B; Mazer JM; Vang A; Harrington EO; Klinger JR; Rounds S; Choudhary G
    Life Sci; 2011 Sep; 89(13-14):460-6. PubMed ID: 21820448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of treprostinil in the SU5416-hypoxia model of severe pulmonary arterial hypertension: haemodynamic benefits are not associated with improvements in arterial remodelling.
    Chaudhary KR; Deng Y; Suen CM; Taha M; Petersen TH; Mei SHJ; Stewart DJ
    Br J Pharmacol; 2018 Oct; 175(20):3976-3989. PubMed ID: 30098019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Selective Transforming Growth Factor-β Ligand Trap Attenuates Pulmonary Hypertension.
    Yung LM; Nikolic I; Paskin-Flerlage SD; Pearsall RS; Kumar R; Yu PB
    Am J Respir Crit Care Med; 2016 Nov; 194(9):1140-1151. PubMed ID: 27115515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of Aquaporin 1 Mediates Increased Migration and Proliferation in Pulmonary Vascular Cells From the Rat SU5416/Hypoxia Model of Pulmonary Hypertension.
    Yun X; Philip NM; Jiang H; Smith Z; Huetsch JC; Damarla M; Suresh K; Shimoda LA
    Front Physiol; 2021; 12():763444. PubMed ID: 34975522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marked Strain-Specific Differences in the SU5416 Rat Model of Severe Pulmonary Arterial Hypertension.
    Jiang B; Deng Y; Suen C; Taha M; Chaudhary KR; Courtman DW; Stewart DJ
    Am J Respir Cell Mol Biol; 2016 Apr; 54(4):461-8. PubMed ID: 26291195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.